Quick Answer
MIRA PHARMACEUTICALS, INC. reported Research And Development Expense of $1.72 million for the year ending 2025.
- MIRA PHARMACEUTICALS, INC. showed a decrease of -48.0% in Research And Development Expense from 2024 to 2025.
- This data is from MIRA PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2022: $715.0 thousand | Q1 2023: $271.6 thousand | Q2 2023: -$101.0 thousand | Q3 2023: $1.02 million | Q1 2024: $762.3 thousand | Q2 2024: $614.5 thousand | Q3 2024: $1.07 million | Q1 2025: $314.4 thousand | Q2 2025: $496.2 thousand | Q3 2025: $412.6 thousand.
- Over the full 4 years of available data (2022 to 2025), MIRA PHARMACEUTICALS, INC.'s Research And Development Expense has declined by 26.9%.
- Historical annual values: Fiscal year 2025: $1.72 million | Fiscal year 2024: $3.31 million | Fiscal year 2023: $1.57 million | Fiscal year 2022: $2.35 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: